X0202 SCHEDULE 13G 0002115022 XXXXXXXX LIVE Common Shares, without par value 03/31/2026 0001540159 Edesa Biotech, Inc. 27966L306 100 SPY COURT MARKHAM A6 L3R 5H6 Rule 13d-1(b) Sirenia Capital Management LP b DE 0.00 600000.00 0.00 600000.00 600000.00 N 7.2 IA PN Alex Silverstein b X1 0.00 600000.00 0.00 600000.00 600000.00 N 7.2 HC IN Edesa Biotech, Inc. 100 Spy Court, Markham, ON, Canada L3R 5H6 This statement is filed by: (i) Sirenia Capital Management LP ("Sirenia") with respect to the common shares, without par value ("Common Shares"), of Edesa Biotech, Inc. (the "Issuer") held by SILV Fund, Ltd. (the "Sirenia Fund"), an investment fund it manages; and (ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Shares held by the Sirenia Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act"). The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139. Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 8,348,161 Common Shares outstanding as of February 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 13, 2026. 7.2% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Sirenia Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Sirenia Capital Management LP /s/ Kolby Loft 05/15/2026 Alex Silverstein /s/ Alex Silverstein 05/15/2026